Niramai Health Analytix Raises $500K Seed Round, Pioneering AI-Powered Breast Cancer Early Detection

NIRAMAI™ Health Analytix, a pioneering health tech company dedicated to revolutionizing breast cancer detection, is excited to announce a funding milestone of $500,000. This investment reinforces our commitment to saving lives by enabling early detection of breast cancer in a privacy-aware manner using our unique AI-based technique, Thermalytix®. At the heart of our innovation, Thermalytix® is a non-invasive breast health screening test that leverages proprietary machine learning and deep learning algorithms to analyze temperature distribution on the chest. This breakthrough allows us to automatically generate a quantitative report, offering a definitive breast health score and assisting medical professionals in identifying potentially abnormal lesions at an early stage. The fresh infusion of funds will empower NIRAMAI Health Analytix to expand its research and development efforts, further enhance the accuracy and efficiency of its screening technology, and extend its outreach to new markets. As we continue to refine our approach, we aim to integrate more advanced data analytics capabilities to improve early diagnostic procedures, while also ensuring that patient privacy remains a fundamental priority. This funding milestone not only solidifies our financial foundation but also boosts our drive to bring life-saving technology to underserved communities globally. We remain steadfast in our mission to provide affordable, accurate, and accessible healthcare solutions and to transform the landscape of breast cancer diagnostics. Stay tuned to this page for more updates on our progress, industry developments, and the ongoing evolution of our technology that is changing lives, one screening at a time.